<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365117</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-TI-167</org_study_id>
    <nct_id>NCT01365117</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study in Healthy Volunteers</brief_title>
  <official_title>Phase 1, Single-center, Open-label, Randomized, Crossover Design Clinical Trial in Healthy Normal Volunteers to Evaluate Insulin Exposure and Dose-proportionality Following Inhalation of Technosphere® Insulin Inhalation Powder (3 U and 4 U Insulin/mg) Using the Gen2 Inhaler</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mannkind Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mannkind Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 clinical trial to evaluate insulin exposure using different formulations of
      Technosphere Insulin Inhalation Powder using the Gen2 inhaler in healthy normal volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, single-center, open-label, randomized, crossover clinical trial to evaluate insulin
      exposure using the 3 U/mg and 4 U/mg Technosphere Insulin Inhalation Powder formulations
      administered using the Gen2 inhaler in 31 healthy volunteers. Drop outs will be replaced.
      Each subject will undergo a screening visit and either 4 or 5 days of in clinic stay and
      dosing, depending on randomization schedule.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The relative exposure (Cmax and AUC0-120) of insulin from TI Inhalation Powder as delivered</measure>
    <time_frame>0-120 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by adverse events</measure>
    <time_frame>32 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by Spirometry (FEV1)</measure>
    <time_frame>32 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by vital sign measurements</measure>
    <time_frame>32 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by physical examination findings.</measure>
    <time_frame>32 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by clinical laboratory test results.</measure>
    <time_frame>32 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere® Insulin Inhalation Powder</intervention_name>
    <description>15 subjects in a three-way crossover (three different doses of TI Inhalation Powder [one 20 U, two 20 U and one 40 U cartridges)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Inhaled human insulin and Technosphere Powder</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technosphere® Insulin Inhalation Powder</intervention_name>
    <description>16 subjects in a four-way crossover (four different doses of TI Inhalation Powder [one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)])</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Inhaled human insulin and Technosphere Powder</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking (within the last 6 months) men and women aged 18 to 45 years who are
             considered healthy

          -  Body mass index (BMI) &lt; 32 kg/m2

          -  FEV1 ≥ 80% of the Third National Health and Nutrition Examination Survey (NHANES III)
             predicted

        Exclusion Criteria:

          -  Pre-existing asthma or chronic obstructive pulmonary disease (COPD)

          -  History of coronary artery disease, peripheral vascular disease, or congestive heart
             failure

          -  Blood donation within the previous 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Connolly, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

